| Company Name: | Arena Pharmaceuticals Inc | | | Ticker Symbol: | ARNA | | CIK Number: | 0001080709 | | WWW Address: | http://www.arenapharm.com |
| CEO: | Mr. Amit D. Munshi | | No. of Employees: | 106 |
| Common Issue Type: | CS | | Business Description: | Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors to address major therapeutic areas like cardiovascular & metabolic diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 47.81 |  -1.77 | 47.03 | 49.05 | 49.67 | 50.05 | 47.54 | 856472 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2,353.9 | 49.2 | 0.00 | -2.77 | 0.00 | 0.0 | 0.0 | 50.05 - 14.54 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 47.81 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 2,353.9 | mil |
| Latest Shares Outstanding | 49.2 | mil |
| Earnings pS (EPS) | -2.77 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 134,195 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 43.8 | mil |
| Float as % of Shares Outstanding | 0.9 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 1.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 3.30 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | -400.5 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 8.4 | % |
| Return on Assets (ROA) | -36.0 | % |
| Return on Equity (ROE) | -74.0 | % |
| Return on Capital Invested (ROCI) | -45.9 | % |
| Current Ratio | 3.9 | |
| Leverage Ratio (Assets/Equity) | 1.6 | |
| Interest Cover | -14.7 | |
| Total Debt/Equity (Gearing Ratio) | 0.30 | |
| LT Debt/Total Capital | 22.0 | % |
| Working Capital pS | 4.24 | $ |
| Cash pS | 0.00 | $ |
| Book-Value pS | 11.86 | $ |
| Tangible Book-Value pS | 4.21 | $ |
| Cash Flow pS | -2.17 | $ |
| Free Cash Flow pS | -2.19 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 4.17 | |
| Price/Tangible Book Ratio | 0.00 | |
| Price/Cash Flow | | |
| Price/Free Cash Flow | | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.9 | 1 | 495,571 | 1,569,747 |
| 4 Weeks | 50.05 | 43.06 | 46.39 | 6.9 | 6 | 531,155 | 10,623,110 |
| 13 Weeks | 50.05 | 33.21 | 44.00 | 12.7 | 11 | 1,065,562 | 68,195,993 |
| 26 Weeks | 50.05 | 29.53 | 29.95 | 65.5 | 62 | 924,677 | 115,584,656 |
| 52 Weeks | 50.05 | 14.54 | 16.60 | 198.7 | 185 | 823,184 | 207,442,438 |
| YTD | 50.05 | 30.00 | - | 36.9 | 34 | 960,101 | 113,291,947 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 49.08 | 48.79 | 43.92 | 39.05 | 35.40 | 0.00 | 0.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -0.05 | 0.0 | -0.17 |
| Income | | 0.0 | |
| Dividend | | 0.0 | |
| Capital Spending | | NA | |
| R&D | -22.62 | NA | -18.37 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 8.4 | 8.4 | 116.9 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.09 | 0.09 | 0.35 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 61.59 |
| Current Ratio | 3.9 |
| Quick Ratio (Acid Test) | 3.6 |
| Liquidity Ratio (Cash) | 5.61 |
| Receivables Turnover | 1.9 |
| Average Collection Period | 189 |
| Working Capital/Equity | 100.9 |
| Working Capital pS | 5.30 |
| Cash-Flow pS | -2.02 |
| Free Cash-Flow pS | -2.02 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 10.65 |
| Financial Leverage Ratio (Assets/Equity) | 0.3 |
| Debt Ratio | 18.2 |
| Total Debt/Equity (Gearing Ratio) | 0.30 |
| LT Debt/Equity | 0.28 |
| LT Debt/Capital Invested | 28.9 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | -14.7 |
| Interest/Capital Invested | 2.29 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.00 |
| Tobin's Q Ratio | 7.18 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -25.30 |
| Enterprise Value (EV)/Free Cash Flow | -30.72 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 0.00 |
| Price/Book Ratio - LTM | 4.17 |
| Price/Cash Flow Ratio | |
| Price/Free Cash Flow Ratio - LTM | |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 2.93 |
| Tangible Book Value pS - LTM | 4.21 |
| Book Value pS - LTM | 11.86 |
| Capital Invested pS | 4.21 |
| Cash pS - LTM | 0.00 |
| Cash Flow pS - LTM | -2.17 |
| Free Cash Flow pS - LTM | -2.19 |
| Earnings pS (EPS) | -2.77 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -312.86 |
| Free Cash Flow Margin 5YEAR AVG | -173.72 |
| Net Profit Margin | -3.9 |
| Net Profit Margin - 5YEAR AVRG. | -1.8 |
| Equity Productivity | 0.10 |
| Return on Equity (ROE) | -0.7 |
| Return on Equity (ROE) - 5YEAR AVRG. | -0.9 |
| Capital Invested Productivity | 0.10 |
| Return on Capital Invested (ROCI) | -0.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -0.4 |
| Assets Productivity | 0.10 |
| Return on Assets (ROA) | -0.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | -0.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | |
| EBITDA Margin - LTM | -400.5 |
| EBIT Margin - LTM | -420.6 |
| Pre-Tax Profit Margin | -1.9 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -1.9 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 74,669 |
| Revenue per Employee | 134,195 |
| Net Income per Employee | |
| Average Collection Period | 74,669 |
| Receivables Turnover | 1.9 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 7.49 |
| Assets/Revenue | 10.00 |
| Net Working Capital Turnover | 0.10 |
| Fixed Assets Turnover | 0.37 |
| Total Assets Turnover | 0.1 |
| Revenue per $ Cash | 0.13 |
| Revenue per $ Plant | 0.71 |
| Revenue per $ Common Equity | 0.10 |
| Revenue per $ Capital Invested | 0.10 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 142.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 332.7 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 332.7 |
|
|  
| | |  |  | | |
